Detalhe da pesquisa
1.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264412
2.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707688
3.
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol
; 156(1): 23-31, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791552
4.
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Invest New Drugs
; 33(6): 1187-96, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26403509
5.
An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug.
J Immunol Methods
; 327(1-2): 10-7, 2007 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17716682
6.
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Cancer Chemother Pharmacol
; 79(2): 315-326, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28097385
7.
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Clin Cancer Res
; 22(5): 1095-102, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26581242
8.
TGF-beta signalling-related markers in cancer patients with bone metastasis.
Biomarkers
; 13(2): 217-36, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18270872
9.
Homozygous deletions within the 11q13 cervical cancer tumor-suppressor locus in radiation-induced, neoplastically transformed human hybrid cells.
Genes Chromosomes Cancer
; 39(4): 277-87, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-14978789